Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries
- Conditions
- DexmedetomidineIntrathecalAdjuvantHyperbaric BupivacaineAnalgesiaArthroscopic Anterior Cruciate Ligament Reconstruction
- Interventions
- Registration Number
- NCT06667024
- Lead Sponsor
- Tanta University
- Brief Summary
This study aimed to evaluate the effect of adding low doses of dexmedetomidine to hyperbaric bupivacaine during spinal anesthesia on post operative analgesia characteristics in Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries
- Detailed Description
The anterior cruciate ligament (ACL) is injured frequently during sports participation. Arthroscopic evaluation of patients with acute traumatic hemarthrosis of the knee has repeatedly demonstrated a 60% to 70% incidence of ACL injury.
Postoperative pain should be effectively treated because it represents an important component of postoperative recovery. Effective treatment serves to blunt autonomic, somatic, and endocrine reflexes with a resultant potential decrease in perioperative morbidity.
Dexmedetomidine is a highly selective α2-adrenergic agonist that has been used for premedication and as an adjunct to general anesthesia. It reduces opioid and inhalational anesthetics requirements.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
- Aged from 21 to 50 years.
- Both genders.
- American society of anesthesiologists (ASA) physical status I and II.
- Patients scheduled for arthroscopic anterior cruciate ligament reconstruction surgeries under spinal anesthesia.
- Patient refusal.
- Body Mass Index (BMI) more than 40 kg/m2.
- Patients who were taking analgesics for chronic pain on opioid therapy or have a history of drug abuse.
- Uncooperative patient.
- Patients with coagulation disorders.
- History of local anesthetics allergy.
- Infection at the needle puncture site.
- Patients with significant respiratory, cardiac, renal or hepatic disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Hyperbaric bupivacaine Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only. Dexmedetomidine (study) group Dexmedetomidine and Hyperbaric bupivacaine Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient's height) hyperbaric bupivacaine.
- Primary Outcome Measures
Name Time Method Total morphine consumption 24 hours postoperatively The rescue analgesia was morphine IV bolus of 3 mg with when VAS \> 30. Total morphine consumption in the first 24 hours postoperatively was documented.
- Secondary Outcome Measures
Name Time Method Time to first rescue analgesia request 24 hours postoperatively Time to the first rescue analgesia (time from end of surgery to first dose of morphine administrated) was recorded
Degree of pain 24 hours postoperatively Degree of pain was assessed using Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 100 represents "the worst pain imaginable"). VAS was assessed at PACU, 1, 2, 4, 8, 12, 18, 24 hours postoperatively.
Duration of motor block Intraoperatively Duration of motor block starting from the time when the Bromage score 3 after spinal anesthesia until the time when the Bromage score was 0 postoperative.
Patient satisfaction 24 hours postoperatively Patients' satisfaction was measured 24 hours postoperative using a five-point Likert scale consisting of:
1: Very dissatisfied, 2: Dissatisfied, 3: Unsure, 4: Satisfied, 5: Very satisfiedIncidence of side effects 24 hours postoperatively Incidence of side effects such as Hypotension, Bradycardia, Shivering, nausea, and vomiting) were recorded.
Trial Locations
- Locations (1)
Tanta University
🇪🇬Tanta, El-Gharbia, Egypt